KREBSBEHANDLUNG

European patent · EP2817011 · In force

Register entry

Publication number
EP2817011
Application number
EP13751188
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 21, 2013
Published
Dec 31, 2014
Granted
Jan 5, 2022
Protection ends at the latest
Feb 20, 2033
Next annual fee due
Feb 28, 2027
IPC classes
A61K 31/664 (2006.01)
A61K 31/675 (2006.01)
A61K 31/7068 (2006.01)
A61P 35/00 (2006.01)
A61K 31/685 (2006.01)
Priority
US 201261601438 P 21.02.2012
US 201361756419 P 24.01.2013
PCT application
PCT/US2013/027091 21.02.2013
PCT publication
WO2013/126539 29.08.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 1, 2025

    Change

    Published in Swissreg on 01.03.2025

  3. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  4. Mar 6, 2023

    Change

    Published in Swissreg on 06.03.2023

  5. Nov 16, 2022

    Change

    Published in Swissreg on 16.11.2022

  6. Jan 5, 2022

    Granted

    Published in Swissreg on 05.01.2022

Parties

Holder

ImmunoGenesis, Inc.

909 Fannin, Suite 2000, Houston TX 77010, US

Inventor

KROLL, Stewart

Oakland, CA 94705, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.